DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more



The Role of Serum Leptin Levels in Multiple Sclerosis Disease Activity While on Interferon Beta 1a (Rebif) Treatment

Information source: University of South Florida
ClinicalTrials.gov processed this data on August 20, 2015
Link to the current ClinicalTrials.gov record.

Condition(s) targeted: Multiple Sclerosis

Phase: N/A

Status: Completed

Sponsored by: University of South Florida

Official(s) and/or principal investigator(s):
Stanley J Krolczyk, DO, RPH, Principal Investigator, Affiliation: University of South Florida

Summary

To determine a correlation between serum leptin levels, nitric oxide preceding a relapse and change in leptin and nitric oxide levels during exacerbation in relapsing remitting multiple sclerosis patients.

Clinical Details

Official title: The Role of Leptin Levels in Multiple Sclerosis

Study design: Observational Model: Case-Crossover, Time Perspective: Prospective

Primary outcome: Fasting leptin and nitric oxide testing

Detailed description: This is an observational pilot study in patients with definitive relapsing-remitting multiple sclerosis to determine whether there is a correlation in serum leptin levels and serum nitric oxide levels during a clinically observed increase in disease activity. Each subject will followed for 12 months while taking interferon beta-1a subcutaneous injections 3 times a week.

Eligibility

Minimum age: 18 Years. Maximum age: 60 Years. Gender(s): Both.

Criteria:

Inclusion Criteria:

- Confirmed diagnosis of multiple sclerosis per update of McDonald criteria

- Initiating treatment with interferon beta 1a subcutaneous injection with minimal

dosing of 22mcg.

- 18-60 years of age.

- Women who are not pregnant or breast feeding, and who do not intend to become

pregnant.

- Stable dose of concomitant medications for 30 days prior to baseline. Efforts should

be made to maintain steady doses of concomitant medications for the duration of the study. Exclusion Criteria:

- Treatment on other interferon preparations, glatiramer acetate, in last 30 days or 6

months on Natalizumab, mitoxantrone, cyclosporine or other immunomodulators as determined by the PI.

- Treatment with any other investigational treatments within the past year or treatment

with any investigational treatments for multiple sclerosis within the last year.

- Any progressive form of MS.

- Known Hypersensitivity to interferon beta 1a.

- Inability to administer subcutaneous injections

- Inability to undergo laboratory evaluation.

- Seropositivity for HIV (by medical history)

- Diabetes Mellitus Tyle I or II (by medical history)

- Hepatitis B or C (by medical history)

- Uncontrolled psychiatric disorder.

- Any unstable illness that the investigator's opinion precludes participation in this

study.

- Inability to maintain compliance with study protocol.

- Implanted devices or metal which would contraindicate MRI.

- Clinically significant abnormalities in CBC or CMP

- MMSE <25

Locations and Contacts

USF Health, Tampa, Florida 33612, United States
Additional Information

Related publications:

De Rosa V, Procaccini C, La Cava A, Chieffi P, Nicoletti GF, Fontana S, Zappacosta S, Matarese G. Leptin neutralization interferes with pathogenic T cell autoreactivity in autoimmune encephalomyelitis. J Clin Invest. 2006 Feb;116(2):447-55. Epub 2006 Jan 12.

Musio S, Gallo B, Scabeni S, Lapilla M, Poliani PL, Matarese G, Ohtsu H, Galli SJ, Mantegazza R, Steinman L, Pedotti R. A key regulatory role for histamine in experimental autoimmune encephalomyelitis: disease exacerbation in histidine decarboxylase-deficient mice. J Immunol. 2006 Jan 1;176(1):17-26.

Starting date: December 2009
Last updated: June 14, 2012

Page last updated: August 20, 2015

-- advertisement -- The American Red Cross
 
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2017